AbbVie secured U.S. FDA approval for Decnupaz (pivekimab sunirine), a CD123-targeting antibody-drug conjugate for adults with blastic plasmacytoid dendritic cell neoplasm (BPDCN). The approval caps a pipeline shift for AbbVie that stems from its 2023 ImmunoGen acquisition, which bought the ADC platform and related assets. The decision is supported by data from the global Cadenza study, with the FDA clearance focusing on a population facing limited treatment options. BPDCN is described as ultra-rare and aggressive, and the authorization provides a new targeted option in a high-need space. For AbbVie, the approval extends the company’s antibody-drug conjugate footprint into another hard-to-treat hematologic cancer cohort and adds a commercial anchor as ADC portfolios mature and expand.